Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; hypromellose; macrogol 300; lactose monohydrate; povidone; magnesium stearate; titanium dioxide; purified water; industrial methylated spirit - treatment of advanced prostate cancer in combination with lhrh agonist therapy. prevention of disease flare associated with the use of lhrh agonist.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine, quantity: 10 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; titanium dioxide; peg-40 hydrogenated castor oil; propyl gallate; hyprolose; iron oxide red; hypromellose; macrogol 6000; iron oxide yellow; sodium stearylfumarate; aluminium sodium silicate; lactose; carnauba wax - hypertension.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine, quantity: 5 mg - tablet, modified release - excipient ingredients: carnauba wax; hypromellose; iron oxide red; propyl gallate; macrogol 6000; microcrystalline cellulose; sodium stearylfumarate; iron oxide yellow; lactose; titanium dioxide; peg-40 hydrogenated castor oil; hyprolose; aluminium sodium silicate - hypertension

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine, quantity: 2.5 mg - tablet, modified release - excipient ingredients: lactose; peg-40 hydrogenated castor oil; hyprolose; propyl gallate; iron oxide yellow; sodium stearylfumarate; microcrystalline cellulose; carnauba wax; hypromellose; macrogol 6000; titanium dioxide; aluminium sodium silicate - hypertension. .

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m plus) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, astrazeneca goserelin shrinks the lesions and reduces the symptoms, including pain. astrazeneca goserelin also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. endometrial thinning: use as an endometrial thinning agent prior to endometrial ablation. assisted reproduction: pituitary down regulation in preparation for controlled ovarian superstimulation.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - olaparib, quantity: 50 mg - capsule - excipient ingredients: gellan gum; hypromellose; titanium dioxide; potassium acetate; lauroyl macrogolglycerides; iron oxide black; shellac - olaparib is indicated as monotherapy for the maintenance treatment of patients with platinum-sensitive relapsed brca-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. prior treatment must have included at least 2 courses of platinum-based regimens.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - exenatide, quantity: 2 mg - injection, modified release - excipient ingredients: sucrose; polyglactin - exenatide is indicated for the treatment of type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 5.1 pharmacodynamic properties - clinical trials for available data on different combinations).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - exenatide, quantity: 250 microgram/ml - injection, solution - excipient ingredients: sodium acetate; water for injections; metacresol; glacial acetic acid; mannitol - exenatide is indicated as adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea, or a combination of metformin and a basal insulin, but are not achieving adequate glycaemic control.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - exenatide, quantity: 250 microgram/ml - injection, solution - excipient ingredients: sodium acetate; metacresol; glacial acetic acid; mannitol; water for injections - exenatide is indicated as adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea, or a combination of metformin and a basal insulin, but are not achieving adequate glycaemic control.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - exenatide -